- Home
- BATL vs TVRD Comparison
BATL vs TVRD Comparison
Compare BATL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | TVRD |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 27.5M |
| IPO Year | 2004 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BATL | TVRD |
|---|---|---|
| Price | $1.34 | $1.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 3.5M | 115.8K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.56 | ★ 79.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,043,000.00 | $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $1.00 | $1.50 |
| 52 Week High | $29.70 | $43.65 |
Technical Indicators
Market Signals| Indicator | BATL | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 43.61 |
| Support Level | $1.27 | $1.72 |
| Resistance Level | $1.44 | $2.04 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 32.61 | 44.48 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.